The pharmacologic and clinical effects of medical cannabis

Pharmacotherapy

Volumn 33, Issue 2, 2013, Pages 195-209

  Borgelt, Laura M ^a   Franson, Kari L ^a   Nussbaum, Abraham M ^b   Wang, George S ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

Cannabinoids; Cannabis; Marijuana therapeutics; Medical cannabis; Medical marijuana; Pain; Pharmacology

Indexed keywords

CANNABIDIOL; CANNABIS; DRONABINOL; FLUOXETINE; KETOPROFEN; MORPHINE; NABILONE; NABIXIMOLS; PLACEBO; PRAMIPEXOLE; RITONAVIR; TETRAHYDROCANNABINOL; TRAMADOL;

ANALGESIC ACTIVITY; ARTICLE; ATAXIA; BURNING SENSATION; COLD SENSATION; CONJUNCTIVA IRRITATION; COUGHING; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL PAIN; HUMAN; HYPOTENSION; MENTAL DISEASE; MUSCLE SPASM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARESTHESIA; PEDIATRICS; PHARMACODYNAMICS; POSTOPERATIVE PAIN; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEDATION; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SPASTICITY; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VERTIGO; VOMITING; XEROSTOMIA;

ANIMALS; CANNABIS; CLINICAL TRIALS AS TOPIC; HUMANS; PAIN; PHYTOTHERAPY; RECEPTOR, CANNABINOID, CB1; SPASM; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 84875408832     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1187     Document Type: Article

References (95)

1. Hi HL. An archaeological and historical account of cannabis in China. Econ Bot 1974;28:437-48.
2. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009;5:153-68.
3. Extractum cannabis. In: The pharmacopoeia of the United States of America, 3rd ed. Philadelphia: Lippincott, Grambo & Co., 1851.
4. Cesamet (nabilone) package insert. Meda Pharmaceuticals, 2009. Available from http://www.cesamet.com/pdf/Cesamet-PI-50-count.pdf. Accessed June 20, 2012.
5. Food and Drug Administration. Label and approval history: marinol. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseactionSearch.Label-ApprovalHistory#apphist. Accessed June 20, 2012.
6. Marinol (dronabinol): package insert. Unimed Pharmaceuticals, Inc., September 2004. Available from http://www.fda.gov/ohrms/dockets/dockets/05n0479/ 05N-0479-emc0004-04.pdf. Accessed December 30, 2011.
7. Sativex (nabiximols) package insert (Canada). Bayer Pharmaceuticals, Inc, 2010. Available from http://www.bayer.ca/files/SATIVEX-PM-ENG-11AUG2010-132251. pdf. Accessed June 20, 2012.
8. NY Daily News. Marijuana-based drug Sativex may get FDA approval?, 2012. Available from at http://articles.nydailynews.com/2012-01-22/news/30653996-1- fda-approval-sativexdrug-companies. Accessed June 20, 2012.
9. A study of Sativex for relieving persistent pain in patients with advanced cancer. Clinical Trials.gov, 2011. Available from http:// clinicaltrials.gov/ct2/show/study/NCT01262651?term=sativex+malignancy&rank= 8&show-locs=Y#locn. Accessed June 20, 2012.
10. Sativex for relieving persistent pain in patients with advanced cancer (SPRAY III). Clinical Trials.gov, 2011. Available from http://clinicaltrials. gov/ct2/show/NCT01361607?term=sativex+malignancy&rank=2. Accessed June 20, 2012.
11. Effects of sativex and oral THC on attention, affect, working memory, reversal learning, physiology and brain activation. Clinical Trials.gov, 2011. Available from http://clinicaltrials.gov/ct2/show/NCT01037608. Accessed December 30, 2011.
12. 18 legal medical marijuana states and DC: laws, fees, and possession limits. 2012. Available from http://medicalmarijuana.procon.org/view.resource. php?resourceID=000881. Accessed January 6, 2013.
13. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147(suppl 1):S163-71.
14. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
15. Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010;62:588-631.
16. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002;42:11S-9S.
17. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63.
18. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43.
19. Strougo A, Zuurman L, Roy C, et al. Modelling of the concentration- effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol 2008;22:717-26.
20. Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 2011;43:128-35.
21. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007;82:572-8.
22. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28:409-16.
23. Rosenkrantz H, Fleischman RW, Grant RJ. Toxicity of shortterm administration of cannabinoids to rhesus monkeys. Toxicol Appl Pharmacol 1981;58:118-31.
24. Zuurman L, Ippel AE, Moin E, van Gerven JM. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009;67:5-21.
25. Lopez HH. Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav 2010;58:100-10.
26. Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend 2009;103:107-13.
27. Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA. Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm 2007;64:1037-44.
28. Joy J, Watson S, Benson J (eds). Marijuana and medicine: assessing the science base. Washington, D.C.: National Academy Press, 1999:267.
29. Colorado Department of Public Health and Environment. The Colorado Medical Marijuana Registry. 2011. Available from http://www.cdphe.state.co.us/ hs/medicalmarijuana/statistics.html. Accessed June 20, 2012.
30. Arizona Department of Health Services. Arizona medical marijuana program. 2012. Available from http://www.azdhs.gov/medicalmarijuana/documents/reports/ 120531-Patient-Application-Report.pdf. Accessed June 20, 2012.
31. Novotna A, Mares J, Ratcliffe S, et al. A randomized, doubleblind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex [R], as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31.
32. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16:707-14.
33. Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, Namaka M. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 2010;11:17-31.
34. Leung L. Cannabis and its derivatives: review of medical use. J Am Board Fam Med 2011;24:452-62.
35. Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol 2012;83:1-10.
36. Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009;10:1353-68.
37. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS ONE 2010;5:e14433.
38. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107: 785-96.
39. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIVassociated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21.
40. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo- controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9:506-21.
41. Fiz J, Duran M, Capella D, Carbonell J, Farre M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE 2011;6:e18440.
42. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694-701.
43. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80.
44. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis- based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50- 2.
45. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo- controlled clinical trial. Pain 2007;133:210-20.
46. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
47. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29:2068-79.
48. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106:169-72.
49. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-6.
50. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9- tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88.
51. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;18:84-9.
52. Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15: 139-43.
53. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253.
54. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9:164-73.
55. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53:769-75.
56. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:iii, ix-x, 1-111.
57. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404:84-7.
58. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
59. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
60. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9.
61. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24.
62. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-9.
63. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.
64. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50.
65. Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Archi Phys Med Rehabil 2010;91:703-7.
66. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008;178:1669-78.
67. Dronabinol. DRUGDEX system. Thomson Reuters (Healthcare) Inc.; 2012. Available from http://www.thomsonhc.com. Accessed March 1, 2012.
68. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005;40:2-14.
69. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002;159:379-87.
70. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003;22:453- 60.
71. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 2011;130:216-21.
72. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003;83:1017-66.
73. Malone DT, Hill MN, Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 2010;160:511-22.
74. Ashtari M, Avants B, Cyckowski L, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J Psychiatr Res 2011;45:1055-66.
75. Cohen M, Rasser PE, Peck G, et al. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol 2012;15:297-307.
76. Fergusson DM. Is there a causal linkage between cannabis use and increased risks of psychotic symptoms? Addiction 2010;105:1336-7.
77. Minozzi S, Davoli M, Bargagli AM, Amato L, Vecchi S, Perucci CA. An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results. Drug Alcohol Rev 2010;29:304-17.
78. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010;167:987-93.
79. Lev-Ran S, Segev A, Braw Y, Levkovitz Y. Neurocognitive functions of heavy cannabis using schizophrenia patients. Eur Psychiatry 2012;27:365-8.
80. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008;1:81-98.
81. Han J, Kesner P, Metna-Laurent M, et al. Acute cannabinoids impair working memory through astroglial CB(1) receptor modulation of hippocampal LTD. Cell 2012;148:1039-50.
82. Yucel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 2008;65:694-701.
83. Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology 2011;76:1153-60.
84. Serra G, Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health 2007;3:25.
85. Nussbaum A, Thurstone C, Binswanger I. Medical marijuana use and suicide attempt in a patient with major depressive disorder. Am J Psychiatry 2011;168:778-81.
86. Substance Abuse and Mental Health Services Administration. Results from the 2009 national survey on drug use and health: volume I. Summary of national findings. Office of applied studies, NSDUH Serics H-38A, HHS Publication No. SMA 10- 4586 Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2010.
87. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-91.
88. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Treatment Episode Data Set - Admissions (TEDS-A), 2008 [Computer file]. ICPSR27241-v2. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2010-03-31. doi:10.3886/ICPSR27241.
89. National Poison Data System. Marijuana human exposure data 2000-2010. Available from www.aapcc.org. Accessed August 23, 2011.
90. McGuigan M. Cannabinoids. Goldfrank's toxicologic emergencies. New York: McGraw Hill; 2011.
91. Carstairs SD, Fujinaka MK, Keeney GE, Ly BT. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J Emerg Med 2011;41:e69-e71.
92. Macnab A, Anderson E, Susak L. Ingestion of cannabis: a cause of coma in children. Pediatr Emerg Care 1989;5:238-9.
93. Weinberg D, Lande A, Hilton N, Kerns DL. Intoxication from accidental marijuana ingestion. Pediatrics 1983;71:848-50.
94. Wang GS, Narang SK, Wells K, Chuang R. A case series of marijuana exposures in pediatric patients less than 5 years of age. Child Abuse Negl 2011;35:563-5.
95. Nussbaum AM, Boyer JA, Kondrad EC. "But my doctor recommended pot": medical marijuana and the patient-physician relationship. J Gen Int Med 2011;26:1364-7.